Dupilumab treatment improves quality of life in adult patients with moderate‐to‐severe atopic dermatitis: results from a randomized, placebo‐controlled clinical trial

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 2, 2018-02 ,pp. : e168-e168

John Wiley & Sons Inc

Access to resources Recommend Favorite

Immunologic Effects of Omalizumab in Children with Severe Refractory Atopic Dermatitis: A Randomized, Placebo-Controlled Clinical Trial

By  

International Archives of Allergy and Immunology, Vol. 162, Iss. 1, 2013-06 ,pp. : 89-93

Karger

Access to resources Recommend Favorite

Efficacy and safety of topical JTE‐052, a Janus kinase inhibitor, in Japanese adult patients with moderate‐to‐severe atopic dermatitis: a phase II, multicentre randomized, vehicle‐controlled clinical study

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 2, 2018-02 ,pp. : e169-e169

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of topical JTE‐052, a Janus kinase inhibitor, in Japanese adult patients with moderate‐to‐severe atopic dermatitis: a phase II, multicentre, randomized, vehicle‐controlled clinical study

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 2, 2018-02 ,pp. : 424-432

John Wiley & Sons Inc

Access to resources Recommend Favorite

The efficacy of a health‐related quality‐of‐life intervention during 48 weeks of biologic treatment of patients with moderate to severe psoriasis: results of a multicentre randomized controlled trial

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 4, 2015-10 ,pp. : 1091-1094

John Wiley & Sons Inc

Access to resources Recommend Favorite